More deals ahead for Bristol Myers? CEO Giovanni Caforio touts 'size agnostic' BD strategy
Despite generics eating away at one of Bristol Myers Squibb’s highest sellers last year, Revlimid, CEO Giovanni Caforio maintained on Wednesday’s Q2 call that the company’s “foundation is strong” — and that he has all the tools necessary to keep building, including a fast-progressing late-stage pipeline and an eye for deals of all sizes.
The pharma giant has a lot riding on two assets in particular: its Phase III-ready antithrombotic milvexian, and deucravacitinib, which is due for an FDA decision in September in moderate to severe psoriasis. In the meantime, Caforio said he is on the hunt for more deals like the company’s recent $4.1 billion takeover of Turning Point, which is expected to close this quarter.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.